July 8, 2022
Pfizer Japan is continuing the restriction of shipments for its transthyretin amyloid cardiomyopathy (ATTR-CM) treatment Vyndaqel (tafamidis meglumine) and the drug’s high-dose version, Vynmac. Vyndaqel has been hit by supply delays due to a surge in global demand, which exceeded...read more